The Evolving Role of DNA Damage Response in Overcoming Therapeutic Resistance in Ovarian Cancer

Overview

Journal Cancer Drug Resist

Date 2023 Jul 17

PMID 37457127

Authors

Sara Bouberhan

Liron Bar-Peled

Yusuke Matoba

Varvara Mazina

Lauren Philp

Bo R Rueda

Affiliations

Soon will be listed here.

Abstract

Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or short-lived. Over the last several years, multiple new classes of agents targeting DNA damage response (DDR) mechanisms have advanced through clinical development. In this review, we explore the preclinical rationale for the use of ATR inhibitors, CHK1 inhibitors, and WEE1 inhibitors, emphasizing their application to chemotherapy-resistant and PARPi-resistant ovarian cancer. We also present an overview of the clinical development of the leading drugs in each of these classes, emphasizing the rationale for monotherapy and combination therapy approaches.

Citing Articles

Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements.

Tavares V, Marques I, de Melo I, Assis J, Pereira D, Medeiros R Int J Mol Sci. 2024; 25(3).

PMID: 38339123 PMC: 10856127. DOI: 10.3390/ijms25031845.

Gramicidin, a Bactericidal Antibiotic, Is an Antiproliferative Agent for Ovarian Cancer Cells.

Choi M, Lee C, Kim J, Lee Y, Lee S, Kim H Medicina (Kaunas). 2023; 59(12).

PMID: 38138162 PMC: 10744341. DOI: 10.3390/medicina59122059.

Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2 ovarian cancer cells.

Biegala L, Gajek A, Szymczak-Pajor I, Marczak A, Sliwinska A, Rogalska A Sci Rep. 2023; 13(1):22659.

PMID: 38114660 PMC: 10730696. DOI: 10.1038/s41598-023-50151-y.

References

Wang W, Fang F, Ozes A, Nephew K . Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation. Mol Cancer Ther. 2021; 20(6):1092-1101. PMC: 8172444. DOI: 10.1158/1535-7163.MCT-20-0826. View

Zhang Y, Otterness D, Chiang G, Xie W, Liu Y, Mercurio F . Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 2005; 19(5):607-18. DOI: 10.1016/j.molcel.2005.07.019. View

Do K, Kochupurakkal B, Kelland S, de Jonge A, Hedglin J, Powers A . Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors. Clin Cancer Res. 2021; 27(17):4710-4716. DOI: 10.1158/1078-0432.CCR-21-1279. View

Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N . MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 2010; 9(7):514-22. DOI: 10.4161/cbt.9.7.11115. View

Rajeshkumar N, de Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T . MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011; 17(9):2799-806. PMC: 3307341. DOI: 10.1158/1078-0432.CCR-10-2580. View

Ngoi N, Sundararajan V, Tan D . Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int J Gynecol Cancer. 2020; 30(8):1224-1238. PMC: 7418601. DOI: 10.1136/ijgc-2020-001277. View

Hong D, Infante J, Janku F, Jones S, Nguyen L, Burris H . Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016; 34(15):1764-71. PMC: 5321045. DOI: 10.1200/JCO.2015.64.5788. View

George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi J . A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight. 2017; 2(1):e89760. PMC: 5214535. DOI: 10.1172/jci.insight.89760. View

Moore K, Chambers S, Hamilton E, Chen L, Oza A, Ghamande S . Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2021; 28(1):36-44. DOI: 10.1158/1078-0432.CCR-21-0158. View

10.

Brown J, Chan D, Shank J, Griffith K, Fan H, Szulawski R . Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer. JCI Insight. 2020; 5(11). PMC: 7308054. DOI: 10.1172/jci.insight.133247. View

11.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G . Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13):1302-8. DOI: 10.1200/JCO.2013.51.4489. View

12.

Moore K, Hong D, Patel M, Pant S, Ulahannan S, Jones S . A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021; 16(5):569-589. DOI: 10.1007/s11523-021-00835-0. View

13.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

14.

Oza A, Estevez-Diz M, Grischke E, Hall M, Marme F, Provencher D . A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive -mutant Ovarian Cancer. Clin Cancer Res. 2020; 26(18):4767-4776. DOI: 10.1158/1078-0432.CCR-20-0219. View

15.

Weigelt B, Comino-Mendez I, de Bruijn I, Tian L, Meisel J, Garcia-Murillas I . Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res. 2017; 23(21):6708-6720. PMC: 5728372. DOI: 10.1158/1078-0432.CCR-17-0544. View

16.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

17.

Khan M, Vikramdeo K, Sudan S, Singh S, Wilhite A, Dasgupta S . Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. Semin Cancer Biol. 2021; 77:99-109. PMC: 8665066. DOI: 10.1016/j.semcancer.2021.08.005. View

18.

Farkkila A, Rodriguez A, Oikkonen J, Gulhan D, Nguyen H, Dominguez J . Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in and -Deficient Cells. Cancer Res. 2021; 81(10):2774-2787. PMC: 8323804. DOI: 10.1158/0008-5472.CAN-20-2912. View

19.

Moore K, Secord A, Geller M, Miller D, Cloven N, Fleming G . Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019; 20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. View

20.

Rundle S, Bradbury A, Drew Y, Curtin N . Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017; 9(5). PMC: 5447951. DOI: 10.3390/cancers9050041. View